These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

154 related articles for article (PubMed ID: 12482017)

  • 21. A comparative study of the relative bioavailability of different interferon beta preparations.
    Deisenhammer F; Mayringer I; Harvey J; Dilitz E; Gasse T; Stadlbauer D; Reindl M; Berger T
    Neurology; 2000 Jun; 54(11):2055-60. PubMed ID: 10851362
    [TBL] [Abstract][Full Text] [Related]  

  • 22. [Interferon beta and copolymer-1: mechanism of action and clinical effects in multiple sclerosis].
    Losy J
    Neurol Neurochir Pol; 2000; 34(3 Suppl):63-9. PubMed ID: 10983302
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Contemporary immunomodulatory therapy for multiple sclerosis.
    Rudick RA
    J Neuroophthalmol; 2001 Dec; 21(4):284-91. PubMed ID: 11756861
    [TBL] [Abstract][Full Text] [Related]  

  • 24. The value of economic modeling studies in the evaluation of treatment strategies for multiple sclerosis.
    Detournay B
    Value Health; 2002; 5(1):1-2. PubMed ID: 11873378
    [No Abstract]   [Full Text] [Related]  

  • 25. [Generation change in beta-Interferon announced].
    Froböse R
    Dtsch Med Wochenschr; 2001 Feb; 126(6):A107. PubMed ID: 11233889
    [No Abstract]   [Full Text] [Related]  

  • 26. A cost-utility analysis of interferon beta for multiple sclerosis.
    Parkin D; McNamee P; Jacoby A; Miller P; Thomas S; Bates D
    Health Technol Assess; 1998; 2(4):iii-54. PubMed ID: 9580870
    [No Abstract]   [Full Text] [Related]  

  • 27. Interferon beta-1a and beta-1b for treatment of multiple sclerosis.
    Kappos L
    Lancet; 2002 Nov; 360(9343):1428; author reply 1428-9. PubMed ID: 12424020
    [No Abstract]   [Full Text] [Related]  

  • 28. [Clinical efficacy and safety of long-term immunomodulating therapy with interferon beta].
    Demina TL; Khachanova NV; Davydovskaia MV; Popova NF; Gusev EI
    Zh Nevrol Psikhiatr Im S S Korsakova; 2008; 108(4):24-6. PubMed ID: 18567192
    [No Abstract]   [Full Text] [Related]  

  • 29. Recurrent nephrotic syndrome in patient with multiple sclerosis treated with interferon beta-1a.
    Tola MR; Caniatti LM; Gragnaniello D; Russo M; Stabellini N; Granieri E
    J Neurol; 2003 Jun; 250(6):768-9. PubMed ID: 12862038
    [No Abstract]   [Full Text] [Related]  

  • 30. [Interferon-beta in multiple sclerosis--who is going to be treated?].
    Aarli JA
    Tidsskr Nor Laegeforen; 1999 Sep; 119(21):3114. PubMed ID: 10522472
    [No Abstract]   [Full Text] [Related]  

  • 31. Editorial commentary to Narayanan et al. Axonal metabolic recovery in multiple sclerosis patients treated with interferon beta-1b.
    Matthews PM
    J Neurol; 2001 Nov; 248(11):987. PubMed ID: 11757964
    [No Abstract]   [Full Text] [Related]  

  • 32. What is new in the treatment of multiple sclerosis?
    Weinstock-Guttman B; Jacobs LD
    Drugs; 2000 Mar; 59(3):401-10. PubMed ID: 10776827
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Rapid onset of ulcerative colitis after treatment with interferon β1a in a patient with multiple sclerosis.
    Tuna Y; Başar O; Dikici H; Köklü S
    J Crohns Colitis; 2011 Feb; 5(1):75-6. PubMed ID: 21272812
    [No Abstract]   [Full Text] [Related]  

  • 34. Local pain during REBIF injection is not due to acidic pH.
    Buttmann M; Goebeler M; Rieckmann P
    J Neurol Neurosurg Psychiatry; 2004 Jul; 75(7):1078. PubMed ID: 15201384
    [No Abstract]   [Full Text] [Related]  

  • 35. Editorial: Licensing and Use of New Therapies in MS: Where Are We Going?
    Hurwitz B
    Int MS J; 2005 Aug; 12(2):39-41. PubMed ID: 16417813
    [No Abstract]   [Full Text] [Related]  

  • 36. Interferon-beta therapy in multiple sclerosis: evidence for a clinically relevant dose response.
    Goodin DS
    Drugs; 2001; 61(12):1693-703. PubMed ID: 11693459
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Interferon-beta treatment decreases cholesterol plasma levels in multiple sclerosis patients.
    Morra VB; Coppola G; Orefice G; De Michele G; Vacca G; Filla A; Bonavita V
    Neurology; 2004 Mar; 62(5):829-30. PubMed ID: 15007146
    [No Abstract]   [Full Text] [Related]  

  • 38. Interferon beta treatment in relapsing-remitting multiple sclerosis. A review.
    Grigoriadis N
    Clin Neurol Neurosurg; 2002 Jul; 104(3):251-8. PubMed ID: 12127664
    [No Abstract]   [Full Text] [Related]  

  • 39. A nexus between lipids and multiple sclerosis?
    Zorzon M
    J Neurol Neurosurg Psychiatry; 2013 Nov; 84(11):1181. PubMed ID: 23595948
    [No Abstract]   [Full Text] [Related]  

  • 40. New onset of rheumatoid arthritis during interferon beta-1B treatment in a patient with multiple sclerosis: comment on the case report by Jabaily and Thompson.
    Alsalameh S; Manger B; Kern P; Kalden J
    Arthritis Rheum; 1998 Apr; 41(4):754. PubMed ID: 9550494
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.